This group of “HIV elite controllers” opens up a new area for researchers to discover biological trends that could inform the creation of better HIV treatments and potential vaccines.
The researchers from Abbott, Johns Hopkins University, the National Institute of Allergy and Infectious Diseases, the University of Missouri-Kansas City and the Université Protestante au Congo found that the prevalence of HIV elite controllers was 2.7–4.3% in the DRC, versus 0.1–2% worldwide.
Get the full story on our sister site Drug Discovery & Development.